Xalkori (crizotinib capsules and oral pellets) — Cigna
Non-Small Cell Lung Cancer with Mesenchymal Epithelial Transition (MET) Mutation
Initial criteria
- Patient age ≥ 18 years
- Patient has non-small cell lung cancer with high-level MET amplification OR MET exon 14 skipping mutation
Approval duration
1 year